GPEx® Lightning: Overcoming Challenges to Deliver Difficult-to-Express Proteins
Abstract: Presented at BioProcess International US West (BPI West) 2026, this session addresses the persistent challenges associated with difficult-to-express biologics, including bispecific antibodies and complex recombinant proteins, which often result in low titers, extended timelines, and scalability risks. GPEx® Lightning overcomes these limitations through targeted gene integration into more than 100 actively transcribed genomic dock sites in CHO cells. This approach enables rapid generation of stable, high-performing cell pools within 25 days, reducing development timelines by up to 6–12 weeks compared to conventional methods. The platform delivers high-titer expression, reaching up to 11 g/L for complex molecules, while maintaining consistent performance from small-scale systems such as Ambr250® through GMP manufacturing. Built-in genetic stability supports over 60 generations without the need for antibiotics, ensuring predictable and scalable production. By combining speed, precision, and robustness, GPEx® Lightning enables more reliable development of next-generation biologics from early discovery through commercial manufacturing.